The risk of myocardial infarction in HIV-infected patients receiving HAART: a case report.
With the advent of highly active antiretroviral therapy (HAART), HIV-related morbidity and mortality has declined. Patients are surviving longer but with serious side effects, especially those receiving protease inhibitors (PIs). We report a case of a healthy young man receiving triple therapy with typical angina symptoms that were not recognized by physicians.
Muise
A
A
Department of Family Medicine and HIV Primary Care, Health Centre at 410, St Michael's Hospital, 410 Sherbourne Street, Toronto, Ontario M4X 1K2, Canada.
Arbess
G
G
D000328:Adult; D019380:Anti-HIV Agents / Q000009:adverse effects*; D023241:Antiretroviral Therapy, Highly Active / Q000009:adverse effects*; D004359:Drug Therapy, Combination; D015658:HIV Infections / Q000097:blood / Q000188:drug therapy*; D006801:Humans; D008297:Male; D009203:Myocardial Infarction / Q000139:chemically induced*; D014280:Triglycerides / Q000097:blood
D019380:Anti-HIV Agents; D014280:Triglycerides